Compare CVS Health Corp (CVS) vs ThredUp Inc (TDUP) Price & Performance

CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.

CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.

ThredUp (TDUP) trades at $3.08, down 4.64% amid a bearish technical signal. The company reported Q2 2026 revenue growth of 16.9% to $90.8 million but missed EPS estimates and cut full-year revenue guidance, triggering a sharp stock decline. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Analyst consensus is positive with 57% buy ratings, but recent news highlights shareholder investigations and promotional headwinds.

The outlook is clouded by near-term execution risks and persistent losses, though long-term potential exists if the company can leverage its asset-light model and AI tools to achieve profitability. Key risks include competitive pressures, macroeconomic sensitivity, and the need to improve cost management. Investors should weigh analyst optimism against the company's challenging path to sustained earnings.